



# Automated Identification and Validation to Detect Physiologically Implausible Pulsatile BP Artifacts


Amy Shanks, PhD

Associate Research Scientist

Michigan Medicine







# Two Peer-Reviewed Studies Investigating Incidence of BP Artifacts

- Both prospective observation trials to determine BP artifact incidences
- Completed in Utrecht
- Pediatric patient population
- Kool et al. (2012)
  - NIBP artifact incidence 2.3% (95% CI 1.8-2.9)
  - Invasive BP artifact incidence 14% (95% CI 12-15)
- Hoorweg et al. (2017)
  - NIBP artifact incidence 5.0% (95% CI 4.0-6.0)
  - Invasive BP artifact incidence 7.3% (95% CI 5.9-8.8)

# BP Reduction Algorithms in Previously Published Literature

Author	Patient Population	BP Reduction Algorithm
Sun et al.	<ul style="list-style-type: none"> <li>• Adult</li> <li>• Non-cardiac</li> <li>• LOS <math>\geq</math> 1 day</li> <li>• A-line monitoring cases</li> </ul>	<ul style="list-style-type: none"> <li>• Change of MAP in either direction <math>\geq</math> 50% between measurements</li> <li>• No MAP recordings for <math>\leq</math> 2 minutes</li> </ul>
Oprea et al.	<ul style="list-style-type: none"> <li>• Adult</li> <li>• Non-cardiac</li> <li>• GA</li> <li>• NIBP and Invasive BP monitoring</li> </ul>	<ul style="list-style-type: none"> <li>• MAP &lt; 30 mmHg or MAP &gt; 250 mmHg</li> </ul>
Salmasi et al.	<ul style="list-style-type: none"> <li>• Adult</li> <li>• Non-cardiac</li> <li>• IP only</li> <li>• NIBP and Invasive BP monitoring</li> </ul>	<ul style="list-style-type: none"> <li>• BP documented as artifact by clinician</li> <li>• SBP <math>\geq</math> 300 mmHg or SBP <math>\leq</math> 20 mmHg</li> <li>• SBP <math>\leq</math> DBP + 5 mmHg</li> <li>• DBP <math>\leq</math> 5 mmHg or DBP <math>\geq</math> 225 mmHg</li> <li>• Abrupt SBP changes <math>\geq</math> 80 mmHg within 1 minute between measurements in either direction</li> <li>• Abrupt SBP changes <math>\geq</math> 40 mmHg within 2 minute between measurements in either direction</li> </ul>

**Observational research with no BP artifact reduction algorithms used in the last 10 years: Bijker et al 2007, 2009, 2012, Walsh et al. 2013, Hsieh et al. 2016**

# Creation of BP Reduction Algorithm (BPAA) and Patient Population

- Consensus taken amongst MD's using Delphi methodology of what is a BP artifact value
- Thousands of cases were hand-reviewed to derive the current algorithm values
  
- Adult ASA I-IV patients with pulsatile blood flow
- Non-cardiac GA cases with a minimum of 3 hours of anesthesia monitoring
- Data were drawn from a minimum of 5 MPOG sites
- Exclusion criteria
  - Cases without valid intraoperative timestamps
  - Cases where invasive BP monitoring was used <80% of the case
  - NIBP monitoring cases with only user entered values

# MPOG Blood Pressure Reduction Algorithm

Artifact Code	Rules/Logic
<b>1</b>	Marked as artifact in real-time by the provider (Not included in analysis)
<b>2</b>	$SBP > 150$ and $PP < 30$
<b>3</b>	$SBP \geq 100$ AND $SBP \leq 150$ AND $PP < 15$
<b>4</b>	$SBP < 100$ AND $PP < 10$
<b>5</b>	$SBP > 200$ AND $PP < 50$
<b>6</b>	$SBP \leq 10$ OR $DBP \leq 10$
<b>7</b>	$SBP = DBP = MAP$
<b>8</b>	$MAP < 0$
<b>9</b>	$MAP \geq 140$
<b>10</b>	If any BP is marked as artifact #1, then all BP measurements for that time will be marked as artifact

Note: If artifact code #2-9 is marked for SBP, DBP, or MAP → All BP's for that timestamp are artifacts

# Validation of BP Reduction Algorithm





- Data were divided into 4 cohorts: Invasive BP and NIBP with and without vasoactive medications used
- Manual clinician review of a random subset of cases for each cohort to identify BP artifacts
  - Clinicians blinded to artifact code that was triggered but could see artifacts documented during the case
- Percentage of algorithm artifacts for each case were calculated by cohort
- Calculated sensitivity/specificity by cohort for BPAA compared to clinician review
- Compared BPAA against three observational trials BP reduction algorithms
- Interrater reliability measured using Krippendorff's alpha
  - 1.00 indicates perfect agreement

## Incidence of Artifacts Triggered by Cohorts

	<b>Incidence of artifacts</b>	<b>Range</b>	<b>Krippendorff's Alpha</b>
<b>NIBP Monitoring without BP support</b>	0.43 ± 1.29	0.00 to 5.17	0.33
<b>NIBP Monitoring with BP support</b>	0.51 ± 1.18	0.00 to 5.61	-0.01
<b>IBP Monitoring without BP support</b>	1.61 ± 2.08	0.00 to 8.64	0.81
<b>IBP Monitoring with BP support</b>	3.02 ± 3.39	0.00 to 12.9	0.70

- Previous research demonstrated NIBP artifacts 2.3-5.0% and Invasive BP artifacts 7.3-14% using real-time clinician documentation by an independent observer
- Clinician documented artifacts were included in their calculations

# Sensitivity and Specificity For Detecting MAP Artifacts Across Four Algorithms




● Sensitivity

● Specificity

\* Original research manuscript only looked at IBP monitoring cases.

# Sensitivity and Specificity For Detecting MAP Artifacts Across Four Algorithms



\* Original research manuscript only looked at IBP monitoring cases

# Conclusions

- The pulsatile BP artifact reduction algorithm is statistically superior for invasive BP monitoring with vasoactive medications and invasive BP monitoring without stratification by vasoactive medications to previously published algorithms
- Interrater reliability was good for invasive BP monitoring
- All sensitivities across the algorithms were poor for NIBP cases. However, perhaps looking at percent change from consecutive values is advantageous
- We feel the BP artifact reduction algorithm should be used in future observational research design to allow for consistency and comparability